The Value of Serum Elabela in Preeclamptic Women with and without Fetal Growth Restriction at 34 Weeks of Pregnancy: A Case–Control Study
Background: Reliable screening methods for fetal growth restriction (FGR) are crucial to improve maternal and neonatal outcomes. Preeclampsia (PE) is a specific pregnancy ailment that contributes to FGR. Elabela (Ela), a newly discovered adipokine, was correlated with PE. Objective: As a marker of P...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Medical Journal of Babylon |
| Subjects: | |
| Online Access: | https://doi.org/10.4103/MJBL.MJBL_1375_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849727998624792576 |
|---|---|
| author | Eham Amer Ali Amenah Fadhil Shaymaa Khalid Abdulqader Wassan Nori Mustafa Ali Kassim Kassim Alexandru Cosmin Pantazi |
| author_facet | Eham Amer Ali Amenah Fadhil Shaymaa Khalid Abdulqader Wassan Nori Mustafa Ali Kassim Kassim Alexandru Cosmin Pantazi |
| author_sort | Eham Amer Ali |
| collection | DOAJ |
| description | Background: Reliable screening methods for fetal growth restriction (FGR) are crucial to improve maternal and neonatal outcomes. Preeclampsia (PE) is a specific pregnancy ailment that contributes to FGR. Elabela (Ela), a newly discovered adipokine, was correlated with PE. Objective: As a marker of PE, we aimed to examine Ela’s role in PE women with and without FGR as a possible screening biomarker at 34 weeks of gestation. Materials and Methods: A case–control study started from March 2022 to December 2022 recruited gestational age and body-indexed matched pregnant at 34 weeks into two groups. Healthy controls (55/110) and PE cases (55/110), were further stratified into (15/55) FGR-PE and (40/55) PE-without FGR. Demographics (systolic and diastolic blood pressure and body mass index), biochemical (creatinine, urea, uric acid, urinalysis, alanine transaminase, and aspartate transaminase), hematological (hemoglobin and platelets), and ultrasonic parameters [gestational age, fetal weight, umbilical artery pulsatility index (PI), and amniotic fluid index] were compared for both. Maternal serum Ela was checked by an enzyme-linked immunosorbent assay kit. Results: Serum Ela was significantly low in FGR-PE (10.02 ± 1.63) cases, followed by PE (11.77 ± 1.02) and healthy controls (17.58 ± 2.72), P < 0.001. Ela was significantly inversely correlated with systolic and diastolic blood pressures (r = -0.41, -0.50), respectively; moreover, it was positively and significantly linked to fetal weight and umbilical artery PI (r = 0.42, 0.35), respectively. Conclusion: Strong and significant correlations of serum Ela with FGR markers at high sensitivity 87% and specificity82%, P < 0.001 in PE moms make it a reliable screening for FGR in PE cases. Future studies are warranted for possible therapeutic and prognostic applications in practice. |
| format | Article |
| id | doaj-art-c3aee2cbf3cc4c84871fc402ceaba28a |
| institution | DOAJ |
| issn | 1812-156X 2312-6760 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Medical Journal of Babylon |
| spelling | doaj-art-c3aee2cbf3cc4c84871fc402ceaba28a2025-08-20T03:09:42ZengWolters Kluwer Medknow PublicationsMedical Journal of Babylon1812-156X2312-67602025-01-0122127528110.4103/MJBL.MJBL_1375_23The Value of Serum Elabela in Preeclamptic Women with and without Fetal Growth Restriction at 34 Weeks of Pregnancy: A Case–Control StudyEham Amer AliAmenah FadhilShaymaa Khalid AbdulqaderWassan NoriMustafa Ali Kassim KassimAlexandru Cosmin PantaziBackground: Reliable screening methods for fetal growth restriction (FGR) are crucial to improve maternal and neonatal outcomes. Preeclampsia (PE) is a specific pregnancy ailment that contributes to FGR. Elabela (Ela), a newly discovered adipokine, was correlated with PE. Objective: As a marker of PE, we aimed to examine Ela’s role in PE women with and without FGR as a possible screening biomarker at 34 weeks of gestation. Materials and Methods: A case–control study started from March 2022 to December 2022 recruited gestational age and body-indexed matched pregnant at 34 weeks into two groups. Healthy controls (55/110) and PE cases (55/110), were further stratified into (15/55) FGR-PE and (40/55) PE-without FGR. Demographics (systolic and diastolic blood pressure and body mass index), biochemical (creatinine, urea, uric acid, urinalysis, alanine transaminase, and aspartate transaminase), hematological (hemoglobin and platelets), and ultrasonic parameters [gestational age, fetal weight, umbilical artery pulsatility index (PI), and amniotic fluid index] were compared for both. Maternal serum Ela was checked by an enzyme-linked immunosorbent assay kit. Results: Serum Ela was significantly low in FGR-PE (10.02 ± 1.63) cases, followed by PE (11.77 ± 1.02) and healthy controls (17.58 ± 2.72), P < 0.001. Ela was significantly inversely correlated with systolic and diastolic blood pressures (r = -0.41, -0.50), respectively; moreover, it was positively and significantly linked to fetal weight and umbilical artery PI (r = 0.42, 0.35), respectively. Conclusion: Strong and significant correlations of serum Ela with FGR markers at high sensitivity 87% and specificity82%, P < 0.001 in PE moms make it a reliable screening for FGR in PE cases. Future studies are warranted for possible therapeutic and prognostic applications in practice.https://doi.org/10.4103/MJBL.MJBL_1375_23fetal growth restrictionfetal weightpreeclampsiapulsatility indexserum elabela |
| spellingShingle | Eham Amer Ali Amenah Fadhil Shaymaa Khalid Abdulqader Wassan Nori Mustafa Ali Kassim Kassim Alexandru Cosmin Pantazi The Value of Serum Elabela in Preeclamptic Women with and without Fetal Growth Restriction at 34 Weeks of Pregnancy: A Case–Control Study Medical Journal of Babylon fetal growth restriction fetal weight preeclampsia pulsatility index serum elabela |
| title | The Value of Serum Elabela in Preeclamptic Women with and without Fetal Growth Restriction at 34 Weeks of Pregnancy: A Case–Control Study |
| title_full | The Value of Serum Elabela in Preeclamptic Women with and without Fetal Growth Restriction at 34 Weeks of Pregnancy: A Case–Control Study |
| title_fullStr | The Value of Serum Elabela in Preeclamptic Women with and without Fetal Growth Restriction at 34 Weeks of Pregnancy: A Case–Control Study |
| title_full_unstemmed | The Value of Serum Elabela in Preeclamptic Women with and without Fetal Growth Restriction at 34 Weeks of Pregnancy: A Case–Control Study |
| title_short | The Value of Serum Elabela in Preeclamptic Women with and without Fetal Growth Restriction at 34 Weeks of Pregnancy: A Case–Control Study |
| title_sort | value of serum elabela in preeclamptic women with and without fetal growth restriction at 34 weeks of pregnancy a case control study |
| topic | fetal growth restriction fetal weight preeclampsia pulsatility index serum elabela |
| url | https://doi.org/10.4103/MJBL.MJBL_1375_23 |
| work_keys_str_mv | AT ehamamerali thevalueofserumelabelainpreeclampticwomenwithandwithoutfetalgrowthrestrictionat34weeksofpregnancyacasecontrolstudy AT amenahfadhil thevalueofserumelabelainpreeclampticwomenwithandwithoutfetalgrowthrestrictionat34weeksofpregnancyacasecontrolstudy AT shaymaakhalidabdulqader thevalueofserumelabelainpreeclampticwomenwithandwithoutfetalgrowthrestrictionat34weeksofpregnancyacasecontrolstudy AT wassannori thevalueofserumelabelainpreeclampticwomenwithandwithoutfetalgrowthrestrictionat34weeksofpregnancyacasecontrolstudy AT mustafaalikassimkassim thevalueofserumelabelainpreeclampticwomenwithandwithoutfetalgrowthrestrictionat34weeksofpregnancyacasecontrolstudy AT alexandrucosminpantazi thevalueofserumelabelainpreeclampticwomenwithandwithoutfetalgrowthrestrictionat34weeksofpregnancyacasecontrolstudy AT ehamamerali valueofserumelabelainpreeclampticwomenwithandwithoutfetalgrowthrestrictionat34weeksofpregnancyacasecontrolstudy AT amenahfadhil valueofserumelabelainpreeclampticwomenwithandwithoutfetalgrowthrestrictionat34weeksofpregnancyacasecontrolstudy AT shaymaakhalidabdulqader valueofserumelabelainpreeclampticwomenwithandwithoutfetalgrowthrestrictionat34weeksofpregnancyacasecontrolstudy AT wassannori valueofserumelabelainpreeclampticwomenwithandwithoutfetalgrowthrestrictionat34weeksofpregnancyacasecontrolstudy AT mustafaalikassimkassim valueofserumelabelainpreeclampticwomenwithandwithoutfetalgrowthrestrictionat34weeksofpregnancyacasecontrolstudy AT alexandrucosminpantazi valueofserumelabelainpreeclampticwomenwithandwithoutfetalgrowthrestrictionat34weeksofpregnancyacasecontrolstudy |